SI3710485T1 - Konjugati protitelo proti-SEZ6-zdravilo in postopki uporabe - Google Patents

Konjugati protitelo proti-SEZ6-zdravilo in postopki uporabe

Info

Publication number: SI3710485T1
Authority: SI; Slovenia
Prior art keywords: antibody; administration; methods; sez6; conjugates
Prior art date: 2018-05-30

Application number

SI201930050T

Other languages

English (en)

Inventor

David Liu

Julia Gavrilyuk

Alexander Schammel

Original Assignee

Abbvie Stemcentrx Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-05-30

Filing date

2019-05-30

Publication date

2021-08-31

2019-05-30 Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc

2021-08-31 Publication of SI3710485T1 publication Critical patent/SI3710485T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Pulmonology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SI201930050T 2018-05-30 2019-05-30 Konjugati protitelo proti-SEZ6-zdravilo in postopki uporabe SI3710485T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201862678061P	2018-05-30	2018-05-30
EP19732174.8A EP3710485B8 (en)	2018-05-30	2019-05-30	Anti-sez6 antibody drug conjugates and methods of use
PCT/US2019/034701 WO2019232241A1 (en)	2018-05-30	2019-05-30	Anti-sez6 antibody drug conjugates and methods of use

Publications (1)

Publication Number	Publication Date
SI3710485T1 true SI3710485T1 (sl)	2021-08-31

Family

ID=66998493

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201930050T SI3710485T1 (sl)	2018-05-30	2019-05-30	Konjugati protitelo proti-SEZ6-zdravilo in postopki uporabe

Country Status (32)

Country	Link
US (4)	US20210196834A1 (sl)
EP (2)	EP3858863A1 (sl)
JP (1)	JP6936399B2 (sl)
KR (1)	KR20210018316A (sl)
CN (1)	CN112135843A (sl)
AU (1)	AU2019278870A1 (sl)
BR (1)	BR112020024223A2 (sl)
CA (1)	CA3097199A1 (sl)
CL (1)	CL2020003044A1 (sl)
CO (1)	CO2020016151A2 (sl)
CR (1)	CR20200623A (sl)
CY (1)	CY1124183T1 (sl)
DK (1)	DK3710485T3 (sl)
EC (1)	ECSP20082970A (sl)
ES (1)	ES2867148T3 (sl)
HR (1)	HRP20210631T1 (sl)
HU (1)	HUE053616T2 (sl)
IL (1)	IL278225A (sl)
LT (1)	LT3710485T (sl)
MA (1)	MA51453A (sl)
MX (1)	MX2020012788A (sl)
NZ (1)	NZ768778A (sl)
PE (1)	PE20211497A1 (sl)
PH (1)	PH12020551968A1 (sl)
PL (1)	PL3710485T3 (sl)
PT (1)	PT3710485T (sl)
RS (1)	RS61770B1 (sl)
RU (1)	RU2770474C1 (sl)
SG (1)	SG11202011576VA (sl)
SI (1)	SI3710485T1 (sl)
SM (1)	SMT202100368T1 (sl)
WO (1)	WO2019232241A1 (sl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102819556B1 (ko)	2021-05-10	2025-06-13	강원대학교산학협력단	항체 결합 재조합 융합 단백질 및 이를 이용한 항체-약물 접합체
WO2022240117A1 (ko)	2021-05-10	2022-11-17	강원대학교 산학협력단	항체 결합 재조합 융합 단백질 및 이를 이용한 항체-약물 접합체
WO2024042497A1 (en) *	2022-08-26	2024-02-29	Abbvie Inc.	Anti-sez6 antibody drug conjugates
CN121152805A (zh)	2023-05-08	2025-12-16	上海翰森生物医药科技有限公司	一种抗体或其抗原结合片段、抗体-药物偶联物及其应用
WO2025167503A1 (en) *	2024-02-05	2025-08-14	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	Anti-sez6/b7h3 antibodies and uses thereof
CN120365421B (zh) *	2025-04-24	2025-11-04	成都古格尔生物技术有限公司	一种特异性抗sez6靶点的全人源抗体及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1319120C (en)	1985-04-01	1993-06-15	John Henry Kenten	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
US5879936A (en)	1988-04-18	1999-03-09	Aluguisse Holding A.G.	Recombinant DNA methods, vectors and host cells
PT2371392E (pt) *	2002-05-02	2015-10-07	Wyeth Holdings Llc	Conjugados de derivado da caliqueamicina - transportador
AR048098A1 (es) *	2004-03-15	2006-03-29	Wyeth Corp	Conjugados de caliqueamicina
AU2005267722B2 (en)	2004-08-04	2009-10-08	Amgen Inc.	Antibodies to Dkk-1
WO2012031273A2 (en)	2010-09-03	2012-03-08	Stem Centrx, Inc.	Novel modulators and methods of use
PE20150091A1 (es) *	2012-02-24	2015-02-16	Stem Centrx Inc	Anticuerpos anti-sez6 y metodos de empleo
US11432900B2 (en)	2013-07-03	2022-09-06	Histosonics, Inc.	Articulating arm limiter for cavitational ultrasound therapy system
EP3038634A4 (en) *	2013-08-28	2017-10-11	AbbVie Stemcentrx LLC	Novel sez6 modulators and methods of use
AU2014312215B2 (en)	2013-08-28	2020-02-27	Abbvie Stemcentrx Llc	Site-specific antibody conjugation methods and compositions
MA41645A (fr) *	2015-03-04	2018-01-09	Abbvie Stemcentrx Llc	Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
EP3285807A4 (en) *	2015-04-21	2018-12-26	Abbvie Stemcentrx LLC	Calicheamicin constructs and methods of use
EP3394106A1 (en) *	2015-12-22	2018-10-31	Abbvie Stemcentrx LLC	Novel anti-mmp16 antibodies and methods of use
EP3468993A1 (en) *	2016-06-08	2019-04-17	AbbVie Inc.	Anti-b7-h3 antibodies and antibody drug conjugates

2019
- 2019-05-30 SG SG11202011576VA patent/SG11202011576VA/en unknown
- 2019-05-30 WO PCT/US2019/034701 patent/WO2019232241A1/en not_active Ceased
- 2019-05-30 EP EP21157876.0A patent/EP3858863A1/en not_active Withdrawn
- 2019-05-30 LT LTEP19732174.8T patent/LT3710485T/lt unknown
- 2019-05-30 HR HRP20210631TT patent/HRP20210631T1/hr unknown
- 2019-05-30 MX MX2020012788A patent/MX2020012788A/es unknown
- 2019-05-30 US US16/904,463 patent/US20210196834A1/en not_active Abandoned
- 2019-05-30 PL PL19732174T patent/PL3710485T3/pl unknown
- 2019-05-30 MA MA051453A patent/MA51453A/fr unknown
- 2019-05-30 PE PE2020001901A patent/PE20211497A1/es unknown
- 2019-05-30 ES ES19732174T patent/ES2867148T3/es active Active
- 2019-05-30 SI SI201930050T patent/SI3710485T1/sl unknown
- 2019-05-30 NZ NZ768778A patent/NZ768778A/en unknown
- 2019-05-30 RS RS20210516A patent/RS61770B1/sr unknown
- 2019-05-30 JP JP2020534838A patent/JP6936399B2/ja active Active
- 2019-05-30 SM SM20210368T patent/SMT202100368T1/it unknown
- 2019-05-30 EP EP19732174.8A patent/EP3710485B8/en active Active
- 2019-05-30 RU RU2020141419A patent/RU2770474C1/ru active
- 2019-05-30 KR KR1020207037003A patent/KR20210018316A/ko not_active Ceased
- 2019-05-30 CA CA3097199A patent/CA3097199A1/en active Pending
- 2019-05-30 CN CN201980033447.XA patent/CN112135843A/zh active Pending
- 2019-05-30 DK DK19732174.8T patent/DK3710485T3/da active
- 2019-05-30 HU HUE19732174A patent/HUE053616T2/hu unknown
- 2019-05-30 BR BR112020024223-3A patent/BR112020024223A2/pt not_active Application Discontinuation
- 2019-05-30 CR CR20200623A patent/CR20200623A/es unknown
- 2019-05-30 AU AU2019278870A patent/AU2019278870A1/en active Pending
- 2019-05-30 PT PT197321748T patent/PT3710485T/pt unknown
2020
- 2020-06-22 US US16/908,645 patent/US11077203B2/en active Active
- 2020-10-21 IL IL278225A patent/IL278225A/en unknown
- 2020-11-18 PH PH12020551968A patent/PH12020551968A1/en unknown
- 2020-11-24 CL CL2020003044A patent/CL2020003044A1/es unknown
- 2020-12-23 EC ECSENADI202082970A patent/ECSP20082970A/es unknown
- 2020-12-23 CO CONC2020/0016151A patent/CO2020016151A2/es unknown
2021
- 2021-04-29 CY CY20211100371T patent/CY1124183T1/el unknown
- 2021-07-09 US US17/372,354 patent/US20210338831A1/en not_active Abandoned
2025
- 2025-02-27 US US19/065,518 patent/US20250213714A1/en active Pending

Also Published As

Publication number	Publication date
EP3710485B8 (en)	2021-06-23
PL3710485T3 (pl)	2021-09-13
CN112135843A (zh)	2020-12-25
EP3858863A1 (en)	2021-08-04
HRP20210631T1 (hr)	2021-05-28
RS61770B1 (sr)	2021-05-31
PE20211497A1 (es)	2021-08-11
US11077203B2 (en)	2021-08-03
JP6936399B2 (ja)	2021-09-15
HUE053616T2 (hu)	2021-07-28
MA51453A (fr)	2020-09-23
EP3710485B1 (en)	2021-03-31
SG11202011576VA (en)	2020-12-30
CR20200623A (es)	2021-07-01
CA3097199A1 (en)	2019-12-05
DK3710485T3 (da)	2021-05-10
PH12020551968A1 (en)	2021-09-13
CO2020016151A2 (es)	2021-05-31
US20210196834A1 (en)	2021-07-01
US20200316215A1 (en)	2020-10-08
CL2020003044A1 (es)	2021-04-16
ECSP20082970A (es)	2021-01-29
ES2867148T3 (es)	2021-10-20
CY1124183T1 (el)	2022-05-27
PT3710485T (pt)	2021-05-04
IL278225A (en)	2020-11-30
KR20210018316A (ko)	2021-02-17
EP3710485A1 (en)	2020-09-23
AU2019278870A1 (en)	2020-10-29
NZ768778A (en)	2022-07-01
SMT202100368T1 (it)	2021-07-12
LT3710485T (lt)	2021-05-10
US20210338831A1 (en)	2021-11-04
MX2020012788A (es)	2021-02-15
RU2770474C1 (ru)	2022-04-18
JP2021508694A (ja)	2021-03-11
US20250213714A1 (en)	2025-07-03
BR112020024223A2 (pt)	2021-03-16
WO2019232241A1 (en)	2019-12-05

Publication	Publication Date	Title
IL284273A (en)	2021-08-31	Antibody drug conjugates (adc) containing saponin
SI3515487T1 (sl)	2023-09-29	Bispecifična protitelesa proti-MUC16-CD3 in konjugati zdravil proti-MUC16
PL3626825T3 (pl)	2024-12-16	Przeciwciało anty-cdh6 i koniugat przeciwciała anty-cdh6 z lekiem
SI3423105T1 (sl)	2021-12-31	Konjugati protitelo-zdravilo na osnovi eribulina in postopki uporabe
SI3710485T1 (sl)	2021-08-31	Konjugati protitelo proti-SEZ6-zdravilo in postopki uporabe
EP3572428A4 (en)	2020-12-30	ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20
IL272534A (en)	2020-03-31	Anthracycline-based antibody drug conjugates having high in vivo tolerability
IL280317A (en)	2021-03-01	Anti-avb8 antibodies and compositions and uses thereof
SI3383916T1 (sl)	2022-06-30	Protitelesa proti-CD73 in njihove uporabe
ZA201801957B (en)	2020-07-29	Pyrrolobenzodiazepine antibody drug conjugates and methods of use
DK3458479T3 (da)	2021-02-08	Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
ZA201801401B (en)	2019-08-28	Anti-dll3 antibody drug conjugates and methods of use
MA47468A (fr)	2019-12-18	Anticorps anti-ilt3 et conjugués anticorps-médicament
DK3458102T3 (da)	2020-07-27	Anti-cmet-antistoflægemiddelkonjugater og fremgangsmåder til anvendelse deraf
PL4190355T3 (pl)	2025-02-10	Formulacje ludzkich przeciwciał anty-RANKL i sposoby ich zastosowania
EP3638697A4 (en)	2021-07-07	ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
PL3618928T3 (pl)	2023-05-02	Przeciwciała antysortylinowe i sposoby ich stosowania
SI3826667T1 (sl)	2024-09-30	Protitelesa Claudin6 in metode zdravljenja raka
EP3612567A4 (en)	2020-11-11	ANTI-BODY-VTCN1 ANTIBODIES AND ANTI-BODY-DRUG CONJUGATES
DK3941946T3 (da)	2025-03-24	Claudin-6-antistoffer og lægemiddelkonjugater
EP3559043A4 (en)	2020-08-05	ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
IL283787A (en)	2021-07-29	Herboxidiene antibody-drug conjugates and methods of use
DK3525828T3 (da)	2025-02-17	Anti-edb-antistoffer og antistoflægemiddelkonjugater
MA49273A (fr)	2020-02-05	Anticorps anti-tmeff1 et conjugués anticorps-médicament
DK3544637T3 (da)	2021-01-18	Native omv-antigenkonjugater og anvendelse deraf